Immuron granted patent for anti-influenza product
Wednesday, 02 March, 2011
Melbourne-based Immuron scored a win today with the granting of an Australian patent for its influenza prevention product, Imm-255.
The patent, issued by the Australian Patents Office, provides protection through to 2028.
Imm-255 uses dairy-derived polyclonal influenza-specific antibodies, which are applied to oral and respiratory surfaces.
The antibodies have to date shown positive results in treating and preventing influenza in mice and ferrets, including treating H1N1.
Once animal trials have concluded, Immuron intends to proceed towards clinical trials in humans.
Immuron's (ASX:IMC) stock dropped $0.004 to 7.1c in morning trading.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
